Clinical trials: Body Weight Control
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Obesity
Dose-Ranging Study of SKF7® for Obesity
This study has been designed as a randomized, double blinded, multi-centric, placebo controlled and phase II dose-ranging study.
- Trial name
- NCT05851599
- Testing
- SKF7® Labisia pumila standardized extract
- Where
- 6 sites in Malaysia
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Medika Natura Sdn Bhd
Obesity, Overweight
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
- Trial name
- NCT00785408
- Testing
- AC2307
- Where
- 18 sites in United States
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT05794581
- Testing
- CT-868, Victoza
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Metabolism and Nutrition Disorder, Obesity
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
- Trial name
- NCT02835235
- Testing
- NNC9204-0530
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.
Obesity, Overweight
A Study of GZR18 Injection in Obese/Overweight Patients
This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
- Trial name
- NCT06256562
- Testing
- GZR18
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage
The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes…
- Trial name
- NCT04433273
- Testing
- Electrical vestibular nerve stimulation
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Diabetes Mellitus, Obesity
An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.
- Trial name
- NCT00806338
- Testing
- Trodusquemine (MSI-1436)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Genaera Corporation
Obesity
Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Roche and GSK will carry out a meta-analysis of liver function data from trials of orlistat to establish whether there is any indication of liver toxicity.
- Trial name
- NCT01332448
- Testing
- Orlistat 120, Orlistat 60
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Obesity
A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.
- Trial name
- FGFR4-CS2 (NCT02476019)
- Testing
- ISIS-FGFR4RX
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
The purpose of this study is to evaluate the safety and efficacy of LMT1-48(Probiotics) compared to a placebo in reducing the body fat in overweight subjects
- Trial name
- NCT03759743
- Testing
- LMT1-48
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Medy-Tox
Overweight, Healthy
A Study of LY3541105 in Healthy and Overweight Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it…
- Trial name
- NCT05380323
- Testing
- LY3541105
- Where
- 2 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company